Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Available 1

Sponsor Class

OTHER 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Neuroblastoma 9Glioma 3Astrocytoma 3Neuroectodermal Tumors, Primitive 2Medulloblastoma 2Glioblastoma 2Typical Teratoid Rhabdoid Tumor 1Sarcoma, Ewing 1Rhabdoid Tumor 1Osteosarcoma 1Oligodendroglioma 1Lymphoma, Follicular 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1

Interventions

Cyclophosphamide 10Temozolomide 8Radiotherapy 6Magnetic Resonance Spectroscopy 6Cisplatin 6Filgrastim 5Etoposide 5Carboplatin 5Vincristine 4sargramostim 3Thiotepa 3Melphalan 3Carmustine 3Automobiles 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3fludarabine 2antineoplaston AS 2-1 2antineoplaston A10 2aldesleukin 2Thalidomide 2Paclitaxel 2Irinotecan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Gadolinium DTPA 2Eflornithine 2Donepezil 2Biopsy 2Bevacizumab 2veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × Eflornithine × CNS × Clear all
NCT06465199 2026-06-03

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
289 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT03581240 2026-02-20

An Intermediate Expanded Use Trial of DFMO

Milton S. Hershey Medical Center

Available
CNS

Typical Teratoid Rhabdoid Tumor, Medulloblastoma, Neuroblastoma, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡